{"id":"https://openalex.org/W7214975362","doi":"https://doi.org/10.3389/fphar.2026.1850131","title":"Efficacy and safety of first- versus second-generation fibroblast growth factor receptor (FGFR) inhibitors in advanced or metastatic urothelial carcinoma with FGFR alterations: a systematic review and meta-analysis","display_name":"Efficacy and safety of first- versus second-generation fibroblast growth factor receptor (FGFR) inhibitors in advanced or metastatic urothelial carcinoma with FGFR alterations: a systematic review and meta-analysis","publication_year":2026,"publication_date":"2026-09-30","ids":{"openalex":"https://openalex.org/W7214975362","doi":"https://doi.org/10.3389/fphar.2026.1850131","pmid":"https://pubmed.ncbi.nlm.nih.gov/42877619","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13662917"},"language":"en","primary_location":{"id":"doi:10.3389/fphar.2026.1850131","doi":"https://doi.org/10.3389/fphar.2026.1850131","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1850131","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1850131/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1850131/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5153558017","display_name":"Zhe Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210161255","display_name":"Liaoning Cancer Hospital & Institute","ror":"https://ror.org/05d659s21","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210161255"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Zhe Wang","raw_affiliation_strings":["Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute","institution_ids":["https://openalex.org/I4210161255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5153589360","display_name":"Bo Shao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210161255","display_name":"Liaoning Cancer Hospital & Institute","ror":"https://ror.org/05d659s21","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210161255"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Bo Shao","raw_affiliation_strings":["Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute","institution_ids":["https://openalex.org/I4210161255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080057262","display_name":"Danxue Huang","orcid":"https://orcid.org/0009-0000-3855-922X","observed_orcids":["https://orcid.org/0009-0000-3855-922X"]},"institutions":[{"id":"https://openalex.org/I4210161255","display_name":"Liaoning Cancer Hospital & Institute","ror":"https://ror.org/05d659s21","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210161255"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Danxue Huang","raw_affiliation_strings":["Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute","institution_ids":["https://openalex.org/I4210161255"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5045777835","display_name":"Liyuan Ke","orcid":"https://orcid.org/0009-0005-0398-6885","observed_orcids":["https://orcid.org/0009-0005-0398-6885"]},"institutions":[{"id":"https://openalex.org/I4210161255","display_name":"Liaoning Cancer Hospital & Institute","ror":"https://ror.org/05d659s21","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210161255"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Liyuan Ke","raw_affiliation_strings":["Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute","institution_ids":["https://openalex.org/I4210161255"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5045777835"],"corresponding_institution_ids":["https://openalex.org/I4210161255"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.59324696,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":"1850131","last_page":"1850131"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.9789999723434448,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.9789999723434448,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":0.01889999955892563,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fgfr-inhibitors","display_name":"FGFR inhibitors","score":0.9079999923706055},{"id":"https://openalex.org/keywords/fgfr-alterations","display_name":"FGFR alterations","score":0.9089999794960022},{"id":"https://openalex.org/keywords/urothelial-carcinoma","display_name":"urothelial carcinoma","score":0.8889999985694885},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.8370000123977661},{"id":"https://openalex.org/keywords/disease-control-rate","display_name":"disease control rate","score":0.9909999966621399},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.9649999737739563},{"id":"https://openalex.org/keywords/hyperphosphatemia","display_name":"hyperphosphatemia","score":0.9710000157356262},{"id":"https://openalex.org/keywords/stomatitis","display_name":"stomatitis","score":0.9539999961853027},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.4909999966621399}],"concepts":[{"id":"https://openalex.org/C82867764","wikidata":"https://www.wikidata.org/wiki/Q24780051","display_name":"Fibroblast growth factor receptor","level":4,"score":0.9110000133514404},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7164000272750854},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4997999966144562},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4894999861717224},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.48410001397132874},{"id":"https://openalex.org/C74373430","wikidata":"https://www.wikidata.org/wiki/Q24727126","display_name":"Fibroblast growth factor","level":3,"score":0.373199999332428},{"id":"https://openalex.org/C49418065","wikidata":"https://www.wikidata.org/wiki/Q14914258","display_name":"Fibroblast growth factor receptor 1","level":4,"score":0.3707999885082245},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.36980000138282776},{"id":"https://openalex.org/C2911057145","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Metastatic Urothelial Carcinoma","level":5,"score":0.3637000024318695},{"id":"https://openalex.org/C3019882237","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Urothelial carcinoma","level":4,"score":0.3529999852180481},{"id":"https://openalex.org/C114276007","wikidata":"https://www.wikidata.org/wiki/Q14897899","display_name":"Fibroblast growth factor 23","level":4,"score":0.3357999920845032},{"id":"https://openalex.org/C2777546739","wikidata":"https://www.wikidata.org/wiki/Q33525","display_name":"Carcinoma","level":2,"score":0.3098999857902527},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2953000068664551},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2816999852657318},{"id":"https://openalex.org/C3020745361","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Urothelial cancer","level":4,"score":0.27720001339912415},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.27000001072883606},{"id":"https://openalex.org/C66400584","wikidata":"https://www.wikidata.org/wiki/Q5446458","display_name":"Fibroblast growth factor receptor 4","level":5,"score":0.2621000111103058},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.25679999589920044},{"id":"https://openalex.org/C2780352672","wikidata":"https://www.wikidata.org/wiki/Q504775","display_name":"Bladder cancer","level":3,"score":0.25369998812675476}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.3389/fphar.2026.1850131","doi":"https://doi.org/10.3389/fphar.2026.1850131","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1850131","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1850131/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13662917","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13662917/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13662917/pdf/fphar-17-1850131.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Pharmacol","raw_type":"Text"},{"id":"pmid:42877619","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42877619","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in pharmacology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:80ef30a03cab4c4d9cd5e86597d7588f","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/80ef30a03cab4c4d9cd5e86597d7588f","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Pharmacology, Vol 17 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fphar.2026.1850131","doi":"https://doi.org/10.3389/fphar.2026.1850131","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1850131","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1850131/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Systematic Review","id":"https://openalex.org/study-designs/systematic-review"},{"display_name":"Meta-Analysis","id":"https://openalex.org/study-designs/meta-analysis"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7214975362.pdf","grobid_xml":"https://content.openalex.org/works/W7214975362.grobid-xml"},"referenced_works_count":45,"referenced_works":["https://openalex.org/W1893740135","https://openalex.org/W1964435302","https://openalex.org/W2017044005","https://openalex.org/W2089735482","https://openalex.org/W2098923148","https://openalex.org/W2101562875","https://openalex.org/W2125435699","https://openalex.org/W2128288739","https://openalex.org/W2148562299","https://openalex.org/W2157244703","https://openalex.org/W2157823046","https://openalex.org/W2279744703","https://openalex.org/W2589079843","https://openalex.org/W2791585439","https://openalex.org/W2805915033","https://openalex.org/W2903848939","https://openalex.org/W2946128073","https://openalex.org/W2951548994","https://openalex.org/W2964014383","https://openalex.org/W2990627920","https://openalex.org/W3008919747","https://openalex.org/W3012052621","https://openalex.org/W3112538276","https://openalex.org/W3118442307","https://openalex.org/W3128646645","https://openalex.org/W3160588632","https://openalex.org/W3167001840","https://openalex.org/W3196749431","https://openalex.org/W4205486610","https://openalex.org/W4297518691","https://openalex.org/W4306249353","https://openalex.org/W4311033849","https://openalex.org/W4378072400","https://openalex.org/W4379334529","https://openalex.org/W4386529928","https://openalex.org/W4387063462","https://openalex.org/W4387847725","https://openalex.org/W4387849835","https://openalex.org/W4388591525","https://openalex.org/W4392284056","https://openalex.org/W4394868958","https://openalex.org/W4399381294","https://openalex.org/W4400738647","https://openalex.org/W4402565847","https://openalex.org/W4402638098"],"related_works":["https://openalex.org/W4407700584","https://openalex.org/W4405173032","https://openalex.org/W7136518230","https://openalex.org/W4405492323","https://openalex.org/W3048907562","https://openalex.org/W2937762787","https://openalex.org/W3031135592","https://openalex.org/W4407482347","https://openalex.org/W7165383260","https://openalex.org/W7212008087"],"abstract_inverted_index":{"Introduction:":[0],"We":[1,41],"reviewed":[2],"the":[3,14,21,43,53,83,97],"clinical":[4,24],"studies":[5,70],"on":[6,72],"fibroblast":[7],"growth":[8],"factor":[9],"receptor":[10],"(FGFR)":[11],"inhibitors":[12,76,127,137,197,201,239,249],"for":[13,35,110],"treatment":[15,33],"of":[16,23,65,124,134],"urothelial":[17],"carcinoma":[18],"to":[19,29,94,108,143,150,160,167,206,213,241],"conduct":[20],"meta-analysis":[22],"efficacy":[25,80,254],"and":[26,46,50,57,96,122,182,230,255],"safety,":[27,256],"aiming":[28],"provide":[30],"more":[31,233],"precise":[32],"options":[34],"patients":[36,67,111],"with":[37,112,116,194,223],"FGFR":[38,75,113,117,126,136,184,196,200,224,238,243,248],"alterations.":[39],"Method:":[40],"performed":[42],"literature":[44],"search":[45],"screening,":[47],"then":[48],"calculated":[49],"analyzed":[51],"using":[52],"STATA":[54],"14.0":[55],"software":[56],"Review":[58],"Manager":[59],"5.3":[60],"software.":[61],"Results:":[62],"A":[63],"total":[64],"1528":[66],"from":[68],"seventeen":[69],"focusing":[71],"seven":[73],"different":[74],"were":[77,128,178,190,232],"collected.":[78],"The":[79,119,172,218,246],"analysis":[81,174],"indicated":[82,175],"pooled":[84,98,120],"objective":[85],"response":[86],"rate":[87,101],"(ORR)":[88],"was":[89,103],"32%":[90],"(95%":[91,105],"CI":[92,106,141,148,158,165,204,211],"26%":[93],"39%)":[95],"disease":[99],"control":[100],"(DCR)":[102],"64%":[104],"53%":[107],"75%)":[109],"alterations":[114],"treated":[115],"inhibitors.":[118,244],"ORR":[121],"DCR":[123],"second-generation":[125,183,195,237,247],"both":[129,253],"significantly":[130,191],"higher":[131],"than":[132],"those":[133],"first-generation":[135,199,242],"(ORR:":[138],"0.35,":[139],"95%":[140,147,157,164,203,210],"0.29":[142],"0.41":[144],"versus":[145,162,198,208],"0.07,":[146],"0.02":[149],"0.16,":[151],"p":[152,169,215],"<":[153,170],"0.001;":[154],"DCR:":[155],"0.68,":[156],"0.61":[159],"0.75":[161],"0.27,":[163],"0.16":[166],"0.40,":[168],"0.001).":[171],"safety":[173],"any-grade":[176],"TRAEs":[177,189],"comparable":[179],"between":[180],"first-":[181],"inhibitors,":[185,225],"but":[186,257],"grade":[187],"\u22653":[188],"less":[192],"frequent":[193],"(0.49,":[202],"0.40":[205],"0.57":[207,212],"0.67,":[209],"0.76;":[214],"=":[216],"0.006).":[217],"common":[219],"target":[220],"toxicities":[221],"associated":[222],"such":[226],"as":[227],"hyperphosphatemia,":[228],"stomatitis":[229],"PPES,":[231],"frequently":[234],"occurred":[235],"in":[236,252],"compared":[240],"Conclusion:":[245],"have":[250],"advantages":[251],"special":[258],"adverse":[259],"reactions":[260],"still":[261],"require":[262],"additional":[263],"attention.":[264]},"counts_by_year":[],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2026-10-01T00:00:00"}